How clinicians tell when pain and fatigue come from inflammation

Picture a 27-year-old whose lower back hurts most at about 4 a.m. The ache wakes her, and she gets out of bed stiff. By mid-morning, after the walk to the bus, it has loosened. A lazy weekend on the couch makes it worse, not better. Her blood test for inflammation comes back normal, and she’s told it’s probably a strain.

That rhythm, pain that eases with movement and worsens with rest, is a classic clue to inflammatory back pain. The normal blood test is less reassuring than it sounds. In the studies pooled for North American referral recommendations published in September 2026, only about 35% of people with chronic back pain who turned out to have axial spondyloarthritis, an inflammatory disease of the spine and pelvic joints, had a raised C-reactive protein (CRP) level.

Here is how clinicians tell inflammatory pain and fatigue from other kinds, and where the blood tests and the inflammation explanation fall short.

Inflammatory and mechanical pain keep different hours

Clinicians start with two plain questions: what makes it better, and what makes it worse? Pain from strain, overuse or joint wear, which doctors call mechanical pain, usually builds with activity and settles with rest. Inflammatory pain often runs the other way.

The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) describes the most common symptom of ankylosing spondylitis, one form of axial spondyloarthritis, as pain and stiffness in the low back or hips. It typically gets worse during rest or inactivity, and movement and exercise usually help. Most people notice symptoms before age 45, and NIAMS lists marked tiredness among the possible symptoms.

Compare osteoarthritis. NIAMS says its joint pain comes with use and may get better with rest, and its stiffness, in the morning or after sitting still, usually lasts less than 30 minutes. Rheumatoid arthritis sits at the inflammatory end. The American College of Rheumatology’s patient page, updated in February 2025, describes morning stiffness that lasts more than an hour and improves with movement. It calls symptoms that last longer than six weeks a sign of persistent inflammation.

So the clock matters, but neither pattern proves anything by itself, and the research on that point is humbling.

No single clue settles the question

In a 2006 study in Arthritis & Rheumatism, a Berlin team led by Martin Rudwaleit compared 213 adults under 50 with chronic back pain, 101 with ankylosing spondylitis and 112 with mechanical back pain. Several features helped tell them apart: morning stiffness lasting more than 30 minutes, pain that improves with exercise but not rest, waking from back pain only in the second half of the night, and buttock pain that switches sides.

But the authors found that no single feature separated the two groups well enough. Combinations did better. Having at least two of those four features picked up about 70% of the people with spondylitis and correctly cleared about 81% of those with mechanical pain. All of these patients had established disease.

A 2009 definition from the Assessment of SpondyloArthritis international Society (ASAS), built from experts’ judgement of real patients, uses five items: improvement with exercise, pain at night, gradual onset, onset before age 40, and no improvement with rest. Morning stiffness isn’t one of them. These are classification criteria for people who already have chronic back pain, not a test that diagnoses one person.

The newest numbers come from the Spondyloarthritis Research and Treatment Network (SPARTAN), a group of North American clinicians whose referral recommendations appeared in ACR Open Rheumatology in September 2026. Their meta-analysis of 38 studies started from a useful baseline: about 5% of people with chronic back pain have axial spondyloarthritis, roughly 1 in 20.

Against that baseline, the classic clues were weak:

• Inflammatory-type back pain as a whole raised the chance only to about 9%, roughly 1 in 11.
• Morning stiffness moved it from 5% to 7%. The panel dropped it from the checklist because it barely shifted the odds.

Objective findings moved the needle more. Inflammation of the sacroiliac joints, where the spine meets the pelvis, seen on an MRI raised the probability to about 27%, and a positive HLA-B27 gene test to about 18%. The final score applies to adults whose chronic back pain began before age 45. It aims to send rheumatologists patients with roughly a one-in-three chance of the disease, and the authors warn that it should not be used to rule the disease out. Back pain care itself waits for a later entry.

What CRP and ESR can and cannot tell you

The two most widely used blood markers of inflammation measure different things. C-reactive protein is made by the liver in response to inflammation. The erythrocyte sedimentation rate (ESR) times how fast red blood cells sink to the bottom of a tube. According to MedlinePlus, the National Library of Medicine’s consumer health site, inflammation makes red cells stick together in heavier clumps that sink faster.

MedlinePlus says a CRP result shows how much inflammation is present, but not what is causing it or where it is. Infections, inflammatory bowel disease, autoimmune disorders and lung disease such as asthma can raise it. So can smoking, polluted air, insomnia, depression, obesity and menopause hormone therapy. Some medicines and supplements, including magnesium and nonsteroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen and aspirin, may affect the result.

ESR has the same blind spot, and MedlinePlus states the other half directly: a person can have an inflammatory condition and still get a normal ESR. Age, sex, pregnancy, the menstrual cycle, obesity, regular drinking and exercise all shift the number.

In SPARTAN’s pooled studies, an elevated CRP turned up in only 35% of the people who had the disease. When it was high, though, it counted. Because a high CRP was uncommon in people with ordinary back pain, it lifted the probability from 5% to about 17%.

A 2016 review in WMJ, the journal of the State Medical Society of Wisconsin, put the working rule plainly: “As ESR and CRP lack sensitivity or specificity, these tests should be used only in combination with clinical history and physical exam…” The two tests often disagree, the authors added, especially in long-running inflammatory diseases. They are most useful when a clinician’s suspicion is already clearly high or clearly low.

MedlinePlus treats a CRP of about 0.8 to 1.0 milligrams per deciliter or lower as healthy. And a high-sensitivity CRP (hs-CRP) is a different test, used to estimate heart disease risk rather than to explain aching joints or tiredness. Why a single flagged result rarely closes a question is covered in our piece on one out-of-range lab number, and the place of hs-CRP in heart and aging research lies outside this article.

Why diagnosis can take years

Axial spondyloarthritis is not rare. SPARTAN’s authors cite estimates that it affects about 1.4% of US adults, against 0.6% for rheumatoid arthritis. Yet a 2021 meta-analysis of 64 studies from the University of Liverpool, published in Rheumatology, found an average delay of 6.7 years from first symptoms to diagnosis, with no improvement over time. Psoriatic arthritis, by comparison, averaged 2.6 years.

The delays were longer for people whose symptoms started young, people with less formal education, and people without inflammation outside the joints, such as in the eyes or bowel. In the United States, SPARTAN notes, an average delay as long as 14 years has been reported.

Common back pain hides the rarer inflammatory kind, and both patients and health systems add to the wait.

• Beliefs about the disease. A synthesis of 21 qualitative studies of people with early rheumatoid arthritis, published in 2011, found that many had thought of it as a mild illness of older people. They played down or ignored their symptoms and usually sought help once daily activities suffered.
• The system. In a 2011 study at 10 European centres, the median time from first rheumatoid arthritis symptoms to a rheumatologist’s assessment was 24 weeks. The authors describe the first three months after symptoms begin as an important window for treatment.

Autoimmune diseases as conditions, with their own criteria and treatments, are taken up in a later entry on autoimmune disorders.

How inflammation can drain your energy

Some of the clearest evidence that immune signals can produce fatigue directly comes from an unexpected place: cancer treatment.

Cytokines are signalling proteins that immune cells release. A 2008 review in Nature Reviews Neuroscience by Robert Dantzer and colleagues at the University of Illinois described how cytokines released during an infection act on the brain to cause sickness behaviour, the listless, withdrawn state of being ill. When immune activation persists, as in cancer or autoimmune disease, they argued, it can deepen that sickness and lead to depression in vulnerable people.

Researchers at Emory University tested the idea in patients. Interferon-alpha is a cytokine that has been given in high doses as a treatment for malignant melanoma, and depression commonly complicated that treatment. In a double-blind trial of 40 patients, published in The New England Journal of Medicine in 2001, an antidepressant started two weeks before interferon lowered the rate of major depression over the first 12 weeks from 45% on placebo to 11%.

A 2002 analysis of the same trial pulled the symptoms apart:

• Early: fatigue, loss of appetite and pain appeared within two weeks in a large share of patients.
• Later: low mood, anxiety and thinking problems arrived afterward, mostly in people who went on to major depression.
• Different responses: the antidepressant helped depression, anxiety, thinking and pain more than it helped fatigue or appetite.

The authors concluded that different mechanisms probably drive different parts of cytokine-induced sickness. That corrects a common assumption that fatigue linked to inflammation is simply depression by another name.

Keep this in proportion. High-dose interferon floods the body with one immune signal, far from everyday inflammation, and the trial is evidence about mechanism, not a treatment plan. It does fit what the National Cancer Institute tells patients: cancer can prompt the body to release cytokines, and at high levels they can cause fatigue.

Inflammation doesn’t explain all exhaustion

If inflammation were the whole story, people with inflammatory diseases would be the most tired. They aren’t. In an international online survey of 6,120 people with 30 rheumatic diseases, published in Clinical Rheumatology in 2015, severe fatigue affected 41% to 57% of those with a single inflammatory disease such as rheumatoid arthritis, lupus or ankylosing spondylitis. It affected 35% of people with osteoarthritis.

It was most common in fibromyalgia, which the survey did not count among the inflammatory diseases: 82%. Volunteers chose to take part, so the figures are rough, but the ranking is hard to square with inflammation alone.

Treating inflammation helps fatigue, but less than many people expect. A 2016 Cochrane review of 32 randomized trials in rheumatoid arthritis found that biologic drugs, which block specific immune signals, reduced fatigue by a small to moderate amount: about 6.5 points on a 52-point fatigue scale, mostly over 24 weeks or less. Even then, the Cochrane authors wrote, “it is unclear whether the improvement results from a direct action of the biologics on fatigue or indirectly through reduction in inflammation…”

In the terms this library uses, that is positive trial evidence with a contested interpretation. The benefit is real but modest, and its route through inflammation is unproven. The review’s searches ended in 2014.

Fatigue has many sources besides inflammation. What the length of a tired spell can and can’t tell you is the focus of our companion article on acute and chronic fatigue, and the questions a clinician asks about persistent tiredness and fogginess are laid out in the brain fog article.

What the labels on anti-inflammatory pain relievers warn about

Many people use over-the-counter NSAIDs for aches that feel inflammatory. What follows is what their labels and federal regulators say, not dosing advice.

Heart attack and stroke. In a 2015 safety communication, the Food and Drug Administration strengthened its warning that non-aspirin NSAIDs can cause heart attacks and strokes. FDA said the risk can appear as early as the first weeks of use and seems greater at higher doses. It applies whether or not someone already has heart disease. FDA also flagged a higher risk of heart failure, and said the evidence could not show that any one NSAID is definitely riskier or safer than another.

Stomach bleeding. Federal regulations require adult over-the-counter NSAID labels to carry a stomach-bleeding warning. The chance is higher for people who:

• are 60 or older, or have had stomach ulcers or bleeding problems;
• take a blood thinner, a steroid or another NSAID;
• have three or more alcoholic drinks a day while using the product;
• take more, or for longer, than the label directs.

The required label tells users to stop and ask a doctor if they feel faint, vomit blood, have bloody or black stools, or have stomach pain that doesn’t get better. Prescription labels go further, warning that serious bleeding can occur at any time during use and without warning symptoms.

Kidneys and blood pressure. The over-the-counter label also lists situations that call for asking a doctor before use: high blood pressure, heart disease, liver cirrhosis, kidney disease and taking a diuretic. A current prescription ibuprofen label says long-term use has caused kidney injury, with the greatest risk in people with impaired kidney function, heart failure or liver problems, people taking diuretics or ACE inhibitors, and older adults. It also warns of new or worsening high blood pressure, and it rules NSAIDs out around coronary bypass surgery.

Pregnancy. In 2020 FDA said NSAIDs should not be used at 20 weeks of pregnancy or later unless a health professional specifically advises it, because they can cause rare but serious kidney problems in the unborn baby and low amniotic fluid. Low-dose aspirin prescribed for certain pregnancy conditions is not covered by that warning.

Whether an NSAID suits someone with kidney disease, heart disease, high blood pressure or a pregnancy is a decision for the prescriber, pharmacist or prenatal clinician. Chest pain, shortness of breath, weakness on one side of the body or slurred speech calls for 911, whatever pain reliever is involved. Claims that particular foods or supplements calm inflammation get their own scrutiny in our coverage of anti-inflammatory diets.

What to tell a clinician about pain that might be inflammatory

Because the pattern carries so much information, it pays to write these down before the appointment:

• When it began, and your age then. Whether it crept up over weeks or started with an injury, and whether it began before 45.
• Its daily rhythm. The worst time of day, whether it wakes you and at what point in the night, and whether moving or resting eases it.
• Stiffness, in minutes. Time it from getting out of bed until it loosens. “A while” tells a clinician much less than “about 90 minutes.”
• Swelling and how long it has lasted. Which joints, and for how many weeks. Six weeks is the line the American College of Rheumatology draws.
• Clues elsewhere in the body. Episodes of eye inflammation (uveitis), psoriasis or inflammatory bowel disease, and any family history of these or of spondyloarthritis. SPARTAN weighs all of them.
• The fatigue. When it is worst, whether rest restores you, and whether it rises and falls with the pain.
• Everything you’ve taken. Every pain reliever and supplement, how often, and any effect, since some can shift a CRP result.
• Earlier results. Copies of past blood tests and imaging, normal ones included.

One question puts the evidence to work: if the blood tests come back normal and this pattern continues, what happens next? Whether that pattern justifies a rheumatology referral is the referring clinician’s call, and SPARTAN built its score to help with exactly that decision.

Some things shouldn’t wait for an appointment: signs of stomach bleeding while using an NSAID need prompt care, and the heart and stroke symptoms above need 911.

The takeaway

In the best recent data, the inflammatory rhythm of back pain was present in about four in five people who had axial spondyloarthritis, while a raised CRP showed up in only about a third. Neither settles the question alone. A normal CRP or ESR does not rule inflammation out, and a high one does not say where it is or why. And exhaustion, however real, is not proof that inflammation is the cause.

What helps most at an appointment is a precise account: when the pain began, when in the day it peaks, how long the stiffness lasts, and what movement and rest do to it. That account helps a clinician decide which tests are worth ordering and how to read them.

Sources

1. MedlinePlus, National Library of Medicine. “C-Reactive Protein (CRP) Test (last updated June 11, 2025).” medlineplus.gov
2. MedlinePlus, National Library of Medicine. “Erythrocyte Sedimentation Rate (ESR) (last updated December 2, 2024).” medlineplus.gov
3. National Institute of Arthritis and Musculoskeletal and Skin Diseases. “Ankylosing Spondylitis.” niams.nih.gov
4. National Institute of Arthritis and Musculoskeletal and Skin Diseases. “Osteoarthritis.” niams.nih.gov
5. American College of Rheumatology. “Rheumatoid Arthritis (patient fact sheet, updated February 2025).” rheumatology.org
6. U.S. Food and Drug Administration. “FDA Drug Safety Communication: FDA strengthens warning that non-aspirin nonsteroidal anti-inflammatory drugs (NSAIDs) can cause heart attacks or strokes (July 9, 2015).”
7. U.S. Food and Drug Administration. “FDA recommends avoiding use of NSAIDs in pregnancy at 20 weeks or later because they can result in low amniotic fluid (October 15, 2020; content current as of January 27, 2023).” fda.gov
8. Legal Information Institute, Cornell Law School (U.S. Food and Drug Administration regulation). “21 CFR 201.326, Over-the-counter drug products containing internal analgesic/antipyretic active ingredients; required warnings and other labeling.” law.cornell.edu
9. DailyMed, National Library of Medicine. “Ibuprofen Tablets, USP: prescribing information (generic product; label revised August 2024).” dailymed.nlm.nih.gov
10. National Cancer Institute. “Fatigue and Cancer Treatment (updated September 20, 2024).” cancer.gov
11. ACR Open Rheumatology. “Dubreuil M, Danve A, Liew JW, et al. "Spondyloarthritis Research and Treatment Network Recommendations for the Referral of Adults With Chronic Back Pain and Suspected Axial Spondyloarthritis to a Rheumatologist." ACR Open Rheumatol, 2026;8(9):e90129. PubMed. DOI: 10.1002/acr2.90129.” pubmed.ncbi.nlm.nih.gov
12. Arthritis & Rheumatism. “Rudwaleit M, Metter A, Listing J, Sieper J, Braun J. "Inflammatory back pain in ankylosing spondylitis: a reassessment of the clinical history for application as classification and diagnostic criteria." Arthritis Rheum, 2006;54(2):569-78. PubMed. DOI: 10.1002/art.21619.” pubmed.ncbi.nlm.nih.gov
13. Annals of the Rheumatic Diseases. “Sieper J et al. "New criteria for inflammatory back pain in patients with chronic back pain: a real patient exercise by experts from the Assessment of SpondyloArthritis international Society (ASAS)." Ann Rheum Dis, 2009;68(6):784-8. PubMed. DOI: 10.1136/ard.2008.101501.” pubmed.ncbi.nlm.nih.gov
14. Rheumatology (Oxford). “Zhao SS, Pittam B, Harrison NL, Ahmed AE, Goodson NJ, Hughes DM. "Diagnostic delay in axial spondyloarthritis: a systematic review and meta-analysis." Rheumatology (Oxford), 2021;60(4):1620-1628. PubMed. DOI: 10.1093/rheumatology/keaa807.” pubmed.ncbi.nlm.nih.gov
15. Annals of the Rheumatic Diseases. “Raza K et al. "Delays in assessment of patients with rheumatoid arthritis: variations across Europe." Ann Rheum Dis, 2011;70(10):1822-5. PubMed. DOI: 10.1136/ard.2011.151902.” pubmed.ncbi.nlm.nih.gov
16. Annals of the Rheumatic Diseases. “Stack RJ, Shaw K, Mallen C, Herron-Marx S, Horne R, Raza K. "Delays in help seeking at the onset of the symptoms of rheumatoid arthritis: a systematic synthesis of qualitative literature." Ann Rheum Dis, 71(4):493-7 (published online November 2011). PubMed. DOI: 10.1136/ard.2011.155416.” pubmed.ncbi.nlm.nih.gov
17. WMJ (State Medical Society of Wisconsin). “Bray C, Bell LN, Liang H, Haykal R, Kaiksow F, Mazza JJ, Yale SH. "Erythrocyte Sedimentation Rate and C-reactive Protein Measurements and Their Relevance in Clinical Medicine." WMJ, 2016;115(6):317-21. PubMed. PMID: 29094869 (no DOI listed).” pubmed.ncbi.nlm.nih.gov
18. Nature Reviews Neuroscience. “Dantzer R, O'Connor JC, Freund GG, Johnson RW, Kelley KW. "From inflammation to sickness and depression: when the immune system subjugates the brain." Nat Rev Neurosci, 2008;9(1):46-56. PubMed. DOI: 10.1038/nrn2297.” pubmed.ncbi.nlm.nih.gov
19. The New England Journal of Medicine. “Musselman DL et al. "Paroxetine for the prevention of depression induced by high-dose interferon alfa." N Engl J Med, 2001;344(13):961-6. PubMed. DOI: 10.1056/NEJM200103293441303.” pubmed.ncbi.nlm.nih.gov
20. Neuropsychopharmacology. “Capuron L et al. "Neurobehavioral effects of interferon-alpha in cancer patients: phenomenology and paroxetine responsiveness of symptom dimensions." Neuropsychopharmacology, 2002;26(5):643-52. PubMed. DOI: 10.1016/S0893-133X(01)00407-9.” pubmed.ncbi.nlm.nih.gov
21. Clinical Rheumatology. “Overman CL, Kool MB, Da Silva JA, Geenen R. "The prevalence of severe fatigue in rheumatic diseases: an international study." Clin Rheumatol, 35(2):409-15 (published online August 2015). PubMed. DOI: 10.1007/s10067-015-3035-6.” pubmed.ncbi.nlm.nih.gov
22. Cochrane Database of Systematic Reviews. “Almeida C et al. "Biologic interventions for fatigue in rheumatoid arthritis." Cochrane Database Syst Rev, 2016;(6):CD008334. PubMed. DOI: 10.1002/14651858.CD008334.pub2.” pubmed.ncbi.nlm.nih.gov